Delivering therapy where it matters®

NASDAQ | RNXT

A Late-Clinical Stage Biotechnology Company

with lead program in a Phase III registrational clinical trial in pancreatic cancer

LD Micro June 2023

What does cancer look like to you?

It doesn't look like life.

And yet, success is measured by Survival Benefit.

What is "Survival Benefit"?

What does a billion-dollar drug look like in pancreatic cancer?

Nab-paclitaxel (Abraxane)

8.5 vs 6.7 months of survival

= **7-week Survival *"Benefit"***



Von Hoff, et. al., Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine. N ENGL J MED 369;18; 2013

What does a billion-dollar drug look like in pancreatic cancer?

At what cost?

Chemotherapy Side Effects:
Are you aware of them?



What does cancer look like to you?

It doesn't look like life.

And yet, success is measured by Survival Benefit.

What is "Survival Benefit"?

Does it have to be this way?



Imagine

Company Overview

- Founded in 2009 by a physician with first external funding 2012. Last private financing led by Boston Scientific, 2018. IPO, Q 3 2021. HQ: Los Altos, CA
- Developing proprietary drug-delivery Trans-Arterial Micro-Perfusion (TAMP™) platform with goal of improving a treatment's therapeutic index across drug class
- Registrational, **Phase III TIGeR-PaC** study with positive interim analysis announced at AACR 2023, **secondary endpoint data planned to be presented at ESMO World GI June 29, 2023**, & potential study stoppage for significance at 2nd interim analysis
- FDA Orphan Drug Designation granted to RenovoGem™ in pancreatic and bile duct cancers
- Market opportunity estimated >$1B per year in first marketed indication

Pipeline Highlights: Two Registration Opportunities

	Locally Advanced Pancreatic Cancer (LAPC)	Bile Duct Cancer
Status	Positive interim data reported from registrational, randomized Phase III trial (TIGeR-PaC)	Phase II/III randomized, controlled study launch estimated 2H 2023
Key Data	First interim analysis presented at AACR 2023: 6-month improvement in median Overall Survival vs. Standard of Care (Control) >65% reduction in side effects	
Next Steps	Second interim analysis estimated YE 2024*	

U.S. FDA Orphan Drug Designation for 7 Year Market Exclusivity

*Potential for early approval with positive second interim results

Locally-Advanced Pancreatic Cancer (LAPC)

RenovoGem Lead Indication:

LOCALLY ADVANCED PANCREATIC CANCER

Pancreatic Cancer Worldwide Incidence:

495,000 new cases/year with 30% locally advanced at presentation

62,000 / 48,000

134,000 / 131,203

Current Standard of Care:

12 to 18.8-month median Overall Survival

using chemo-radiation regimens with gemcitabine+nab-paclitaxel OR mFOLFIRINOX as base treatment

Soon to be second leading cause of cancer-related death in US

Three Drugs Approved by FDA to Treat PDAC within Past 10 Years

Confidential Do Not Distribute

All Three FDA Approvals (Abraxane, Olaparib, Onivyde) in past 10-years observed <2mo Median Overall Survival Benefits and *Increases* in Toxicity Rates

Highlighting FDA continued concordance of Pancreatic Cancer as High Unmet Need



Nab-paclitaxel (Abraxane) obtained FDA approval in 2013 on a 7-week Median Overall Survival benefit

38% Grade 3 or Higher Neutropenia and 17% Neuropathy



Olaparib received full FDA approval in 4Q 2019 with no Median Overall Survival Difference (a <4-mo PFS benefit);

Onivyde received FDA approval on a 1.9-mo Median OS benefit in 2015

Independent Interviews suggest Community & Academic Medical Oncologists *Likely* to Adopt RenovoGem™ if ~4-month Overall Survival Benefit and Toxicity Improvement



"Any amount of time, if it is from a phase III. **We started using erlotinib about 15 years ago based on a 14-day benefit**." Abushahin, MedOnc, **Ohio State**

The idea of an infusional therapy, **avoiding systemic toxicity is appealing**." Iyer, MedOnc, **Roswell**

This targets local vessel involvement and **you can up the delivery of concentration**." Astsaturov, HemOnc, **Fox Chase**

"What do we do with the [unresectable] patients that don't develop metastatic disease for a while? We've essentially talked only about two lines of treatment. But eventually **toxicity builds up** and they can't tolerate treatment. For that subset of patients…it would be **highly attractive to offer them something like this**." Mettu, MedOnc, **Duke**

Source: FSI Interviews (multiple responses permitted per respondent)

RR3 TIGeR-PaC Phase III Data Update (1st Interim Analysis):

RenovoGem Arm observes **6-month Median Overall Survival** benefit over IV Gem-Abraxane (control)



Data on 45 patients Randomized

- 23 randomized to RenovoGem
- 22 randomized to IV gem/Abraxane (control)

Median Overall Survival (OS) Difference: 6-months

IV Gem Abraxane (control arm)

Avg 5.5 mo dx to randomization

10 mo from randomization

~15.5 Months from diagnosis

Approx. 15.5 months from dx

RenovoGem (test arm)

Avg 5.5 mo dx to randomization

16 mo from randomization

~21.5 Months from diagnosis

Approx. 21.5 months from dx

Data Presented at AACR 2023

Statistical significance was not reached to stop the study early

RR3 TIGeR-PaC Phase III Data Update (1st Interim Analysis)

RenovoGem (treatment) arm observes >65% Fewer AEs and SAEs
compared to standard of care systemic/IV Gem/Abraxane (control), Despite Novel Procedure

Total AEs and SAEs



Locally Advanced Pancreatic Cancer Market Opportunity*

$1B

MARKET OPPORTUNITY*

US: $500M
REST OF WORLD: $500M

New Orphan Drug Product Regulatory and Reimbursement:

- **Orphan Drug Protection** (2 indications)
- Will submit New Drug Application (NDA) approval for RenovoGem
- **National Drug Code (J-Code) reimbursement** upon FDA NDA approval

New Oncology Drug Market

Average new oncology drug pricing: $150,000/year*

Prospective/formal pricing analysis to be conducted with Phase III data prior to commercial launch of RenovoGem

*Fletcher Spaght, 2019

RenovoGem Product Development Plan

	DISCOVERY	PRECLINICAL	PHASE I	PHASE II	PHASE III	COMMERCIAL LAUNCH
LA-Pancreatic Cancer				Registrational, Randomized Phase III TIGeR-PaC Study: 1st Interim Analysis complete; 50 patients randomized		
LA-Bile Duct Cancer (Extrahepatic Cholangiocarcinoma [eCCA])				Phase II/III CouGAr Study: Est Start 2H2023		
Neoadjuvant Pancreatic Cancer			Phase I/II Study Est Start FY2024			
Lung Cancer			Pilot animal study completed			
Uterine Tumors						
Glioblastoma						

Potential Statistical Significance to Stop Study Early at Next Interim Analysis

RenovoGem Broad Market Opportunity in Target Cancers



US Annual Incidence of Initial RenovoGem Target Tumor Types

- 350,000 total patients diagnosed/year
- ~125,000 all locally advanced (stage 3) potentially addressable via RenovoGem

TAMP is broadly applicable to locally advanced tumors:

Platform may be used with multiple small molecule chemotherapeutic agents in multiple solid tumor indications

Trans-Arterial Micro-Perfusion (TAMP) Proprietary Drug Delivery Platform



A New Way: We Are Addressing a Significant Problem in Cancer Treatment



Hypervascular tumors are adequately treated with current therapies

Liver tumors are highly vascularized

- Large tumor feeders – excellent targets for systemic therapy
- Can be accessed and treated with current local therapy techniques



Hypovascular tumors = major barrier to chemotherapy treatment success

Pancreatic tumors have poor blood supply

- No visible tumor feeder vessels
- Systemic chemotherapy does not reach tumor tissue
- Inability to identify or engage tumor feeder vessels: local therapy is ineffective

TAMP Improves a Drug's Therapeutic Index

Higher Amounts of Drug to Pathological Site (⬆**Efficacy**) & Less Systemic Exposure (⬆ **Safety**)

Increases **Drug Concentration to Target Pathological Site** by ~100X* Compared to IV Administration*

Reduces Drug AUC by >50% Compared to IV Administration⁺



Drug Exposure IA vs. IV route



Impact of route of administeratiob on Drug Exposure Area Under the Curve-Normalized for Total Dose (hr*ng/mL/mg, p<0.015)

*As demonstrated in animal studies

⁺ Sub-study performed in Phase 3 TIGeR-PaC study =- presented at ASCO-GI 1023

Our Solution: Trans-Arterial Micro-Perfusion (TAMP) Delivery System
An Enabling Technology For Therapeutic Delivery in Solid Tumors





Mechanism: after vessel isolation, increase in pressure forces drug across the artery wall into the micro-vasculature into tumor tissue





RenovoGem Patient & Physician Experience

Fewer hospital/clinic visits for patients

Easy to learn, quick procedure for interventional radiologists/oncologists

Patient Experience

20-minute infusion; ~90-minute outpatient procedure (shorter for subsequent procedures

8 treatments over 4-months (2x/month hospital visits)

33% less hospital/clinic visits compared to IV Administration (*more time at home with family*)

Clinician Experience

Similar techniques used in liver directed therapies

Shallow learning curve

Physicians demonstrate expertise after 2-3 proctored procedures

Targeted Approach: Designed to Decrease Side Effects and Increase Tumor Penetration

- Reduced systemic drug exposure (compared to systemic chemotherapy)
- Higher local drug concentration

Phase III Lead Drug Product Candidate: RenovoGem

- Drug/Device Combination:
  Intra-arterial gemcitabine (chemotherapy) delivered through FDA cleared RenovoCath delivery system
- Randomized open label registrational Phase III TIGeR-PaC positive interim analysis data released at AACR 2023:
  6-month survival benefit
  65% reduction in side effects
- Additional Phase III data to be presented at ESMO World GI June 29, 2023

Can be Applied to Locally Advanced Solid Tumors

- Initial indications: pancreatic cancer ($1B addressable market) and cholangiocarcinoma
- Potential future indications include non-small cell lung cancer, uterine tumors, glioblastoma, sarcoma
- With AI-imaging techniques and liquid biopsies detecting cancer earlier, a rapidly growing patient population

Novel Therapy Platform: TAMP

- Trans-Arterial Micro-Perfusion compatible with multiple potential targets
- Platform expanding pre-clinical studies underway

TAMP Platform: Layers of Market Exclusivity (Regulatory and IP)

- 8 US patents issued on TAMP, delivery system, and drug/device combination
- Orphan Drug Designation for Pancreatic Cancer and Cholangiocarcinoma provides 7 years of market exclusivity for RenovoGem upon NDA approval

Experienced Management Team Supported by World Class Board of Directors

Shaun R. Bagai
Chief Executive Officer & Board Member

HeartFlow ($1B+ raised)
Ardian (acq for > $900M)
Medtronic Vascular
TransVascular

Ramtin Agah, MD
Chief Medical Officer, Founder & Chairman of the Board

Interventional Cardiology, Sutter Health; Consultant Abbott Vascular

Angela Gill Nelms
Chief Operating Officer

Florence Healthcare
Emory University School of Medicine
Medtronic

Leesa Gentry
Senior Vice President of Clinical Operations

Evotec
Otsuka America Pharmaceuticals
Omnicare Clinical Research

James Ahlers
Chief Financial Officer

Intacria Therapeutics; Titan Pharma; Ansan Pharma

Led or Contributed to the Development of

Fugerel* FLUTAMIDE Tablets
Interferon alfa-2b recombinant Intron A
Zetia (ezetimibe)
Peginterferon alfa-2b PegIntron REDIPEN
DELTYBA delamanid
Remicade INFLIXIMAB
Temodar (temozolomide) for Injection

David Diamond
Board Member

Fmrly Board Oncotelic Therapeutics

Una S. Ryan, PhD, OBE
Board Member

Board: Cortexyme, Elemental Machines

Laurence J. Marton, MD
Board Member

Board: Cellsonics, TOMA Biosciences, xCures

Angela Macfarlane
Board Member

CEO, Perceive Biotherapeutics ($78M raised led by JJDC)
CEO Foresight Labs

Robert J. Spiegel, MD
Board Member

CMO, PTC Therapeutics
CMO, Schering-Plough ($41.1B merger with Merck)

>200 years of combined development / commercial experience

Contributed to *30+ successful New Drug Application filings* with the Food and Drug Administration

Launched multiple blockbuster drugs

Served as executives or board members in companies acquired by Medtronic, Roche, Merck, and Allergan

Upcoming Milestones

Phase III pancreatic cancer interim analysis/secondary endpoint Oral Abstract presentation at ESMO – World GI

Publication of Final Pre-Phase III Data for pancreatic cancer

Identification of third Indication: Clinical trial design and study launch

Phase II/III CouGAr eCCA Study launch (second indication)

2nd Interim Analysis: TIGeR-PaC Phase III pancreatic cancer study

Enrollment and randomization completion: TIGeR-PaC Phase III pancreatic cancer study

Final Data Readout: TIGeR-PaC Phase III pancreatic cancer study

Financial Highlights

$3.7M
CASH & INVESTMENTS*
(AS OF 3/31/23)

$5M
ADDITIONAL GROSS PROCEEDS FROM REGISTERED DIRECT OFFERING
(CLOSED 4/23)

9%
OFFICER & DIRECTOR OWNERSHIP
(AS OF 5/1/23)

$2.08
RNXT/SHARE
(AS OF 6/02/23)

$21M
MARKET CAPITALIZATION
(AS OF 6/02/23)

10.7M
SHARES OUTSTANDING
(AS OF 4/4/23)

* Investments include short-term US treasury bills.

Investment Opportunity

- De-risked drug development and validated TAMP approach
- Large first indication market ($1B) and platform broadly applicable to growing market segment
- Experienced clinical and commercial Leadership Team and Board
- **First RenovoGem Phase III interim analysis completed Q1 ’23 – presented positive results at AACR 2023:**
  - **6-month survival benefit**
  - **>65% reduction in side effects**
- **2nd Phase III interim analysis data presentation at ESMO World GI 6/29/23**

Delivering therapy where it matters®

NASDAQ | RNXT

Company Contact:

Shaun R. Bagai, CEO

sbagai@renovorx.com

+1.650.284.4483

Investor Relations Contact:

KCSA Strategic Communications

Valter Pinto or Jack Perkins | RenovoRx@KCSA.com

+1.212.896.1254

RENOVO | RX